doi:10.3969/j.issn.1004-583X.2023.10.017

Abstract

CLC Number:

R556

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2023.10.017

https://huicui.hebmu.edu.cn/EN/Y2023/V38/I10/949

References 42

[1]	Griffin P. Rodgers. United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2022[DB/OL]. https://usrds-adr.niddk.nih.gov/2022/end-stage-renal-disease/3-clinical-indicators-and-preventive-care.html, 2023-03-10.
[2]	Miyata T, Ueda Y, Horie K, et al. Renal catabolism of advanced glycation end products: The fate of pentosidine[J]. Kidney Int, 1998, 53(2):416-422. pmid: 9461101
[3]	Uribarri J, Del Castillo MD, De La Maza MP, et al. Dietary advanced glycation end products and their role in health and disease[J]. Adv Nutr, 2015, 6(4): 461-473. doi: 10.3945/an.115.008433 pmid: 26178030
[4]	Pageon H, Zucchi H, Rousset F, et al. Glycation stimulates cutaneous monocyte differentiation in reconstructed skin in vitro[J]. Mech Ageing Dev, 2017, 162: 18-26. doi: S0047-6374(16)30135-X pmid: 28163107
[5]	Odetti P, Cosso L, Pronzato MA, et al. Plasma advanced glycosylation end-products in maintenance haemodialysis patients[J]. Nephrol Dial Transplant, 1995, 10(11):2110-2113.
[6]	于敏, 王姣, 史耀勋, 等. 慢性肾衰竭微炎症状态发生机制的研究进展[J]. 中华医院感染学杂志, 2010, 20(10):1498-1500.
[7]	Xu G, Luo K, Liu H, et al. The progress of inflammation and oxidative stress in patients with chronic kidney disease[J]. Ren Fail, 2015, 37(1): 45-49. doi: 10.3109/0886022X.2014.964141 pmid: 25375354
[8]	Syed-Ahmed M, Narayanan M. Immune dysfunction and risk of infection in chronic kidney disease[J]. Adv Chronic Kidney Dis, 2019, 26(1): 8-15. doi: 10.1053/j.ackd.2019.01.004 URL
[9]	Ekdahl KN, Soveri I, Hilborn J, et al. Cardiovascular disease in haemodialysis: Role of the intravascular innate immune system[J]. Nat Rev Nephrol, 2017, 13(5): 285-296. doi: 10.1038/nrneph.2017.17 pmid: 28239169
[10]	Bossola M, Sanguinetti M, Scribano D, et al. Circulating bacterial-derived DNA fragments and markers of inflammation in chronic hemodialysis patients[J]. Clin J Am Soc Nephrol, 2009, 4(2): 379-385. doi: 10.2215/CJN.03490708 URL
[11]	Wang F, Zhang P, Jiang H, et al. Gut bacterial translocation contributes to microinflammation in experimental uremia[J]. Dig Dis Sci, 2012, 57(11): 2856-2862. doi: 10.1007/s10620-012-2242-0 URL
[12]	Fraenkel PG. Anemia of inflammation: A review[J]. Med Clin North Am, 2017, 101(2): 285-296. doi: 10.1016/j.mcna.2016.09.005 URL
[13]	Steinbicker AU, Sachidanandan C, Vonner AJ, et al. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation[J]. Blood, 2011, 117(18): 4915-4923. doi: 10.1182/blood-2010-10-313064 pmid: 21393479
[14]	Yan Z, Xu G. A novel choice to correct inflammation-induced anemia in CKD:oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat[J]. Front Med (Lausanne), 2020, 6(7): 393.
[15]	Ganz T, Longo DL. Anemia of Inflammation[J]. NewEngla nd Journal of Medicine, 2019, 381(12): 1148-1157.
[16]	De Oliveira, Junior WV, Sabino AP, et al. Inflammation and poor response to treatment with erythropoietin in chronic kidney disease[J]. J Bras Nefrol, 2015, 37(2): 255-263. doi: 10.5935/0101-2800.20150039 pmid: 26154647
[17]	Souma T, Yamazaki S, Moriguchi T, et al. Plasticity of renal erythropoietin-producing cells governs fibrosis[J]. J Am Soc Nephrol, 2013, 24(10):1599-1616. doi: 10.1681/ASN.2013010030 pmid: 23833259
[18]	Fujii J, Homma T, Kobayashi S, et al. Erythrocytes as a preferential target of oxidative stress in blood[J]. Free Radic Res, 2021, 55(5): 562-580.
[19]	Hsu SP, Chiang CK, Yang SY, et al. Nacetylcysteine for the management of anemia and oxidative stress in hemodialysis patients[J]. Nephron Clinical Practice, 2010, 116(3): c207-c216. doi: 10.1159/000317201 URL
[20]	Shepshelovich D, Rozen-Zvi B, Avni T, et al. Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis[J]. Am J Kidney Dis, 2016, 68(5): 677-690. doi: S0272-6386(16)30125-1 pmid: 27321965
[21]	Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease[J]. Circulation, 2002, 106(17): 2212-2217. doi: 10.1161/01.cir.0000035250.66458.67 pmid: 12390950
[22]	Stefanova D, Raychev A, Arezes J, et al. Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron[J]. Blood, 2017, 130(3): 245-257. doi: 10.1182/blood-2017-03-772715 pmid: 28465342
[23]	Shah AA, Donovan K, Seeley C, et al. Risk of infection associated with administration of intravenous iron[J]. JAMA, 2021, 4(11):e2133935.
[24]	Li X, Cole SR, Kshirsagar AV, et al. Safety of Dynamic Intravenous Iron Administration Strategies in Hemodialysis Patients[J]. Clinical Journal of the American Society of Nephrology, 2019, 14(5): 728-737. doi: 10.2215/CJN.03970318 pmid: 30988164
[25]	汤莹, 杜光, 孙秋雁. 缺铁性贫血临床药物治疗进展[J]. 中国医院药学杂志, 2022, 23:2560-2566.
[26]	Pergola PE, Kopyt NP. Oral ferric maltol for the treatment of iron-deficiency anemia in patients with CKD: A randomized trial and open-label extension[J]. Am J Kidney Dis, 2021, 78(6): 846-856. doi: 10.1053/j.ajkd.2021.03.020 pmid: 34029682
[27]	Kaplan JM, Sharma N, Dikdan S. Hypoxia-inducible factor and its role in the management of anemia in chronic kidney disease[J]. Int J Mol Sci, 2018, 19(2):389. doi: 10.3390/ijms19020389 URL
[28]	Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis[J]. N Engl J Med, 2019, 381(11): 1011-1022. doi: 10.1056/NEJMoa1901713 URL
[29]	Chen N, Hao C, Peng X, et al. Roxadustat for Anemia in patients with kidney disease not receiving dialysis[J]. N Engl J Med, 2019, 381(11): 1001-1010. doi: 10.1056/NEJMoa1813599 URL
[30]	Besarab A, Provenzano R, Hertel J, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients[J]. Nephrol Dial Transplant, 2015, 30(10): 1665-1673. doi: 10.1093/ndt/gfv302 URL
[31]	周任, 陈亚婷, 张永. 罗沙司他治疗血液透析肾性贫血患者有效性和安全性的Meta分析[J]. 临床荟萃, 2022, 37(4):305-310.
[32]	Su X, Xie Y, Zhang J, et al. HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis[J]. Cell Death Dis, 2022, 13(10):861. doi: 10.1038/s41419-022-05304-8 pmid: 36209275
[33]	D'arrigo G, Baggetta R, Tripepi G, et al. Effects of vitamin e-coated versus conventional membranes in chronic hemodialysis patients: A systematic review and meta-analysis[J]. Blood Purif, 2017, 43(1-3): 101-122. doi: 10.1159/000453444 URL
[34]	Susantitaphong P, Riella C, Jaber BL. Effect of ultrapure dialysate on markers of inflammation, oxidative stress, nutrition and anemia parameters: A meta-analysis[J]. Nephrol Dial Transplant, 2013, 28(2): 438-446. doi: 10.1093/ndt/gfs514 URL
[35]	Zhang Y, Mei CL, Rong S, et al. Effect of the combination of hemodialysis and hemoperfusion on clearing advanced glycation end products: A prospective, randomized, two-stage crossover trial in patients under maintenance hemodialysis[J]. Blood Purif, 2015, 40(2): 127-132. doi: 10.1159/000376604 URL
[36]	Macdougall IC, Bhandari S, White C, et al. Intravenous iron dosing and infection risk in patients on hemodialysis: A prespecified secondary analysis of the PIVOTAL trial[J]. J Am Soc Nephrol, 2020, 31(5): 1118-1127. doi: 10.1681/ASN.2019090972 pmid: 32253271
[37]	Hasegawa T, Zhao J, Fuller DS, et al. Erythropoietin hyporesponsiveness in dialysis patients: Possible role of statins[J]. Am J Nephrol, 2017, 46(1): 11-17. doi: 10.1159/000477217 pmid: 28564644
[38]	Zhu Y, Tang Y, He H, et al. Gut Microbiota correlates with clinical responsiveness to erythropoietin in hemodialysis patients with anemia[J]. Front Cell Infect Microbiol, 2022, 22(12): 919352.
[39]	Sagar P, Angmo S, Sandhir R, et al. Effect of hepcidin antagonists on anemia during inflammatory disorders[J]. Pharmacol Ther, 2021, 226: 107877. doi: 10.1016/j.pharmthera.2021.107877 URL
[40]	Schwoebel F, Van Eijk LT, Zboralski D, et al. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys[J]. Blood, 2013, 121(12): 2311-2315. doi: 10.1182/blood-2012-09-456756 pmid: 23349391
[41]	Van Eijk LT, John AS, Schwoebel F, et al. Effect of the antihepcidin spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans[J]. Blood, 2014, 124(17): 2643-2646. doi: 10.1182/blood-2014-03-559484 pmid: 25163699
[42]	Renders L, Budde K, Rosenberger C, et al. First-in-human phase i studies of prs-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis[J]. PLoS One, 2019, 14(3): e0212023. doi: 10.1371/journal.pone.0212023 URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 42

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Gu Cuihong, Wang Yang, Lin Li, Wang Lihong, Zhang Zhihua. Anti-thymocyte globulin combined with cyclosporine A in the treatment of severe aplastic anemia-induced caplillary leak syndrome in children: A case report [J]. Clinical Focus, 2023, 38(9): 819-322.
[2]	Zhu Weijian, He Ying, Huang Mufang, Fu Shezhu, Wang Xiaoqi, Li Zhixin, Chen Lijun, Li Xiaoliang. Change of miR-223-3p level in peripheral blood of β-thalassemia treated with thalidomide and corresponding clinical value [J]. Clinical Focus, 2022, 37(6): 515-518.
[3]	Wen Xue, Zhang Zhihua, Zhang Rongjuan, Hao Changlai. Hereditary spherocytosis caused by SPTB gene hybrid mutation: a case report [J]. Clinical Focus, 2021, 36(11): 1019-1023.
[4]	. [J]. Clinical Focus, 2016, 31(3): 336-336.
[5]	. [J]. Clinical Focus, 2015, 30(11): 1309-1312.
[6]	Yang Wenrui;Zhang Fengkui. Diagnosis and treatment of acquired aplastic anemia [J]. Clinical Focus, 2015, 30(10): 1081-1086.
[7]	Li Yingmei;Sun Hui. Current status of diagnosis and treatment of autoimmune hemolytic anemia [J]. Clinical Focus, 2015, 30(10): 1087-1091.
[8]	. @@ [J]. Clinical Focus, 2015, 30(10): 1178-1180.
[9]	Shi Xiuzhen;Wang Huiping;Pan Ying;Wang Zhitao;Zhang Jiakui;Zhai Zhimin. Comparison of CD4 + CD25 + Treg cell and T-cell subgroups in evaluating immune status in patients with aplastic anemia [J]. Clinical Focus, 2015, 30(6): 628-632.
[10]	WANG Lu;HAN Bing. Recent progresses in the treatment of aplastic anemia [J]. Clinical Focus, 2014, 29(10): 1083-1086.
[11]	WU Yu;XU Juan. Advances in the treatment of hemolytic anemia [J]. Clinical Focus, 2014, 29(10): 1087-1.09011e+007.
[12]	. @@ [J]. Clinical Focus, 2014, 29(10): 1191-1194.
[13]	. [J]. Clinical Focus, 2014, 29(8): 922-924.
[14]	. [J]. Clinical Focus, 2014, 29(8): 926-927.
[15]	. [J]. Clinical Focus, 2014, 29(5): 565-566.